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Peptide-based vaccine successfully induces protective immunity
against canine visceral leishmaniasis
Elodie Petitdidier 1*, Julie Pagniez 1, Joana Pissarra1, Philippe Holzmuller2,3, Gérard Papierok4, Philippe Vincendeau1,5,
Jean-Loup Lemesre1 and Rachel Bras-Gonçalves 1*
Dogs are the main reservoir of zoonotic visceral leishmaniasis. Vaccination is a promising approach to help control leishmaniasis
and to interrupt transmission of the Leishmania parasite. The promastigote surface antigen (PSA) is a highly immunogenic
component of Leishmania excretory/secretory products. A vaccine based on three peptides derived from the carboxy-terminal part
of Leishmania amazonensis PSA and conserved among Leishmania species, formulated with QA-21 as adjuvant, was tested on naive
Beagle dogs in a preclinical trial. Four months after the full course of vaccination, dogs were experimentally infected with
Leishmania infantum promastigotes. Immunization of dogs with peptide-based vaccine conferred immunity against experimental
infection with L. infantum. Evidence for macrophage nitric oxide production and anti-leishmanial activity associated with IFN-γ
production by lymphocytes was only found in the vaccinated group. An increase in speciﬁc IgG2 antibodies was also measured in
vaccinated dogs from 2 months after immunization. Additionally, after challenge with L. infantum, the parasite burden was
signiﬁcantly lower in vaccinated dogs than in the control group. These data strongly suggest that this peptide-based vaccine
candidate generated cross-protection against zoonotic leishmaniasis by inducing a Th1-type immune response associated with
production of speciﬁc IgG2 antibodies. This preclinical trial including a peptide-based vaccine against leishmaniasis clearly
demonstrates effective protection in a natural host. This approach deserves further investigation to enhance the immunogenicity of
the peptides and to consider the possible engineering of a vaccine targeting several Leishmania species.
npj Vaccines            (2019) 4:49 ; https://doi.org/10.1038/s41541-019-0144-2
INTRODUCTION
Leishmania infections are vector-borne neglected diseases caused
by Leishmania spp. protozoan parasites transmitted by phleboto-
mine sand ﬂies. Currently, they are responsible for the second-
highest number of deaths due to parasitic infections worldwide,
and are overwhelmingly associated with poverty.1,2
Zoonotic visceral leishmaniasis (ZVL) affects both humans and
canids and is caused by Leishmania infantum/Leishmania chagasi in
the Mediterranean region, several Middle Eastern, African and Asian
countries, in South and Central America and probably in southern
US.3,4 Wild and domestic canids are known to be the main reservoir
of parasites, and to continuously supply the transmission cycle of L.
infantum in the old world and L. chagasi in the new world. Canine
visceral leishmaniasis (CVL) is a severe disease characterized by
chronic evolution of viscerocutaneous signs, which is of great
importance in Europe for both public health and in veterinary
medicine. At least 2.5 million dogs are probably infected and
severely affected dogs do not survive.5 Both symptomatically and
asymptomatically infected dogs can be considered as a reservoir of
the parasite involved in the transmission cycle of L. infantum in dogs
and humans.6 In ZVL-endemic regions of the Mediterranean and
Latin America, a high prevalence of canine infection is associated
with a high risk of human disease.7
Prevention of CVL requires reducing transmission of the
parasite, including treatment of dogs based on chemotherapy,
and reducing the population of vectors. Applying insecticides may
have a transitory effect but is typically unsustainable in the long
term for several technical and economic reasons as well as for the
protection of the environment. Although substantial progress has
been made in current drug treatments, this approach cannot be
used to treat asymptomatic infected dogs because they are not
diagnosed and are always at risk of developing leishmaniasis.8
With a view to long-term and cost-effective protection of dogs
and humans against leishmaniasis, preventive vaccination is a very
promising approach and hopefully could also be used to interrupt
the transmission of Leishmania and eliminate leishmaniasis.6
A major limitation in the ﬁeld of leishmaniasis vaccines
concerns the difﬁculty of ﬁnding an animal model that reproduces
the aspects of natural disease and the immune responses required
for efﬁcacy. Past experiments have underlined the danger of
extrapolating results from experimental animal models such as
rodents to human or dog diseases.9 Selection of vaccine
candidates is challenging because of the large number of antigens
to be evaluated with different levels of effectiveness depending
on their formulation and on the animal model used.10 Preclinical
research in rodent models has provided evidence for the efﬁcacy
of several categories of Leishmania antigens including whole
parasites, cell puriﬁed fractions, parasite protein components or
subunits, single or multiple chimeric recombinant proteins,
plasmid DNA and viral particles encoding parasite virulence
factors.10–13 Despite the successful protection conferred by the
many vaccine candidates in rodent models (mouse and hamster),
only two prophylactic vaccine candidates against human leishma-
niasis are now in clinical trials (ClinicalTrial.gov identiﬁers
NCT01011309 and NCT01751048).
Dog is an appropriate model to objectively evaluate the
effectiveness of a vaccine targeted for ZVL. A small number of
vaccine candidates have been tested in dogs14 and four vaccines
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have obtained a commercial license against CVL: (i) Leishmune® in
Brazil, a semi-puriﬁed fucose–mannose ligand antigen (FML)
adjuvanted with Quil-A®.15 However, the Leishmune® license has
been suspended since 2014 as the vaccine did not fulﬁl the phase
III requirements in terms of vaccine efﬁcacy;16 (ii) Leish-Tec®, the
only vaccine currently sold in Brazil, which contains a recombinant
protein A2 adjuvanted with saponin;17 (iii) CaniLeish® in Europe,
composed of L. infantum excreted/secreted products (LiESAp) and
adjuvanted with QA-2118–20 and ﬁnally, (iv) LetiFend®, which
contains Protein Q as active ingredient, has received marketing
authorization by the European Commission.21
Using Leishmania excreted/secreted products, we previously
showed that soluble promastigote surface antigens (PSA) were
characterized as immunodominant excreted/secreted compo-
nents of Leishmania amazonensis and L. infantum.22 We recently
showed that, 6 months after infection with L. infantum, 78.8% of
naive vaccinated dogs with recombinant PSA (rPSA, LaPSA-38S) of
L. amazonensis and 80% of vaccinated dogs with its carboxy-
terminal part (Cter-rPSA), both combined with QA-21 as adjuvant,
were protected against experimental infection.23 This cross-
protection was associated with hallmarks of a dominant Th1-
type immune response. We also clearly demonstrated in L.
infantum and L. major-protected humans (healed individuals),
that a dominant Th1-type response associated with a cytotoxic
response was induced in vitro by rPSA.24 The PSA protein is highly
abundant in the Leishmania secretome, further supporting its use
as a vaccine antigen candidate.22 However, the low yield of rPSA
production precludes its use as second-generation dog or human
vaccine.
The aim of the present study was to evaluate a peptide-based
vaccine candidate made of immunodominant peptides, selected
and derived from the abundant Leishmania rPSA. Indeed, protein
abundance is a key feature for antigen selection, as abundant
proteins are more likely to be processed and presented by major
histocompatibility complex (MHC) molecules to T lymphocytes,
and protein abundance correlates with peptide immunodomi-
nance.25 The results of the present study will help guide research
towards peptide-based synthetic vaccines, as these have many
advantages in terms of safety, efﬁcacy and cross-protection, with
reproducible, cost-effective and large-scale production, to ﬁght
zoonotic parasitic diseases.
RESULTS
Local and general reactions upon vaccination and clinical follow-
up post-infection
Fifteen naive Beagle dogs were enroled in this study and
randomized into two experimental groups: a control group with
ﬁve dogs and a vaccinated group composed of ten dogs. No local
and systemic adverse reactions were observed in any of the dogs
immunized with the peptide-based vaccine candidate or peptide
solvent alone. All the animals maintained constant body condition
and body weight throughout the study. No hyperthermia was
induced. The overall tolerance of the peptide-based vaccine
appeared to be satisfactory in all dogs. No obvious clinical sign of
leishmaniasis was observed in any of the dogs at any time point
during the study.
Parasitological evolution of dogs
Four months after the full course of vaccination (three doses), all
dogs were experimentally infected by intravenous injection of 108
infective promastigotes of L. infantum. Figure 1 shows the
percentages of actively infected positive dogs per group found
by sub-culturing bone marrow aspirates (Fig. 1a) and by detecting
parasite DNA using quantitative polymerase chain reaction (q-
PCR) (Fig. 1b) at 2, 4 and 6 months post-challenge (PC). Results of
parasite cultures were positive in the control group (n= 5), in one
(20%), three (60%) and ﬁve (100%) dogs at 2, 4 and 6 months,
respectively. By contrast, results of parasite cultures in the
vaccinated group (n= 10) were positive in three (30%), four
(40%) and three (30%) animals at the same time points. In detail,
from the three infected dogs at 2 months PC, one of these
remained positive at 4 and 6 months PC, whereas the two other
dogs became negative at these time points. Three new dogs were
found culture positive at 4 months PC, for a total of four infected
dogs. Two of these four dogs became negative at 6 months PC,
the other two dogs remained positive, and one new dog was
found culture positive. By the end of the experiment, three
animals out of ten were positive 6 months PC, revealing again a
signiﬁcant difference in the percentage of actively infected dogs
between the two groups (100% versus 30%, p= 0.019). All the
control dogs were found to be PCR-positive at 4 and 6 months PC
as shown in Fig. 1b. Sixty percent of the vaccinated dogs were
PCR-positive at 2 months PC and 70% at 4 months PC, versus only
40% at 6 months PC, i.e. a signiﬁcant difference from the control
group (p= 0.042). Group data for bone marrow parasite loads are
presented in Fig. 1c. Mean values were signiﬁcantly lower in the
group of vaccinated dogs than in the control group at 4 and
6 months post-infection (p= 0.049 and p= 0.005, respectively).
Speciﬁc IgG2 antibody responses to Leishmania antigens
Speciﬁc IgG2 antibody responses against L. infantum promastigote
excreted/secreted antigens (LiESAp) and E34PC peptide were
measured by enzyme-linked immunosorbent assay (ELISA) in all
serum samples (Fig. 2). Before immunization (T0), all the dogs in
both groups showed a baseline with low levels of speciﬁc IgG2
antibodies. A similar low speciﬁc IgG2 response was observed in
dogs in the control group two (T2) and three (T3) months post-
immunization. By contrast, dogs vaccinated with peptides/QA-
21 showed signiﬁcantly higher levels of anti-LiESAp (p= 0.001 and
p= 0.003, Fig. 2a) and anti-E34PC (p= 0.001 and p= 0.001, Fig.
2b) antibodies at T2 and T3 after immunization, respectively.
Overall, our data show a clear post-vaccination peptide-speciﬁc
IgG2 response in vaccinated dogs.
Development of macrophage anti-leishmanial activity by
vaccination
Anti-leishmanial activity is expressed as a percentage of parasite
index inhibition (Fig. 3). Before immunization (T0), the assay
revealed no signiﬁcant anti-leishmanial activity in any of the dogs
in either the control group or the vaccinated group. By contrast,
statistical differences were found between the vaccinated and
control groups after the full administration of the vaccine. Indeed,
two (T2), three (T3) and four (T4) months post-vaccination,
evidence was found for higher macrophage anti-leishmanial
activity after 72 h exposure of in vitro infected macrophages to
autologous lymphocytes in dogs vaccinated with peptides/QA-21,
as demonstrated by a signiﬁcant parasitic index inhibition: 63%,
75% and 68%, compared to the control group: 24%, 27% and 26%
(p= 0.002, p= 0.001 and p= 0.001), respectively.
Production of IFN-γ cytokine and derivative of nitric oxide
As shown in Fig. 4a, supernatants of infected macrophages co-
cultured with autologous lymphocytes from all the dogs in the
control group expressed low IFN-γ levels (about 0.05 ng/mL), prior
to immunization (T0) and two months after the third injection (T2).
By contrast, at T2, the IFN-γ level was signiﬁcantly higher in co-
cultures of pre-infected macrophages upon activation with
autologous lymphocytes from peptide-vaccinated dogs compared
to the control group (1.81 ± 0.96 ng/mL, p= 0.0013).
At the start of the experiment, infected macrophages from all
dogs produced small quantities of nitric oxide (NO) derivative
(4.91 ± 0.52 nmol/105 cells/72 h, Fig. 4b). At T2, levels of NO
E. Petitdidier et al.
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derivative produced by infected macrophages from vaccinated
dogs were signiﬁcantly higher (12.75 ± 2.52 nmol/105 cells/72 h),
whereas production of NO derivative remained unchanged in cell
supernatants from control dogs (5.8 ± 0.73 nmol/105 cells/72 h,
p= 0.001).
Conservation of peptide sequences among Leishmania species
Among Leishmania species, BLAST analysis identiﬁed the PSA
protein sequences most similar to the LaPSA-38S protein
sequence (GenBank accession number FJ974054; UniprotKB
Fig. 1 Post-challenge parasitological evaluation of placebo control and vaccinated dogs. a The presence of live Leishmania parasites
highlighted by NNN sub-culture analysis of bone marrow aspirates isolated from dogs in the placebo (n= 5) and vaccinated (n= 10) groups at
2, 4 and 6 months post-infection. A sample was considered positive when Leishmania parasites were detected during seeding or sub-culture
analysis. b The presence of Leishmania DNA and c the parasite load in bone marrow aspirates of dogs of each group were assessed by
quantitative PCR. Data are expressed as the percentage of positive dogs (a, b) and the mean number of parasites per millilitre of bone marrow
aspirate (c) at different times post-infection (2, 4 and 6 months). Dots represent individual animals and lines represent means. Asterisks (*)
indicate signiﬁcant mean differences (*p < 0.05, **p < 0.01) measured by Fisher’s Exact test (a and b) or Mann–Whitney–Wilcoxon test (c).
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Fig. 2 Vaccine-speciﬁc serological responses detected by ELISA. a Changes in levels of anti-LiESAp and b anti-E34PC-speciﬁc IgG2 antibodies
in serum samples isolated from dogs in each group before immunization (T0) and two (T2) and three (T3) months after the third dose of
vaccine. Positivity threshold values were calculated using the following formula: mean OD in sera from all dogs at T0+ 3 standard deviations.
Dots represent individual animals and lines represent means. Asterisks (*) indicate signiﬁcant mean differences (**p < 0.01, ***p < 0.001)
measured with the Mann–Whitney–Wilcoxon test.
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D1GJ50), which are: Leishmania mexicana PSA (GenBank accession
number FR799565; UniprotKB E9AP03), Leishmania donovani PSA
(GenBank accession number DQ086111; UniprotKB Q4JI42), L.
infantum PSA (GenBank accession number FJ974055; UniprotKB
D1GJ51), L. major PSA (GenBank accession number FR796408;
UniprotKB Q4QGL4), Leishmania tropica PSA (GenBank accession
number AF164027; UniprotKB Q9NDD1) and Leishmania brazilien-
sis PSA (GenBank accession number FR798986; UniprotKB
A4H6Y8).
Multiple sequence alignment performed with the MUltiple
Sequence Comparison by Log-Expectation (MUSCLE) tool revealed
that the LaPSA-38S protein sequence was very similar to PSA proteins
from other Leishmania species, especially the end amino acid
sequences from which our peptide sequences were derived (Fig. 5a).
The EMBOSS Water tool allowed us to show local pairwise
sequence alignment of the three peptide sequences A17G, A17E
and E34PC and the different PSA protein sequences (Fig. 5b). The
A17G and the original A17E peptide sequences were identical to
part of the carboxy terminal region of the PSA protein sequence
from L. amazonensis and L. mexicana. However, replacing cysteines
by serines in the A17E peptide sequence, to avoid disulphide
bridge formation, reduced the identity to 87.5%. The A17E
sequence was relatively conserved among PSA protein sequences
since it shared at least 60% sequence identity and similarity
with them.
E34PC is composed of two distinct parts of consensus
sequences, EDEHKGKYCRLGNDCRTT and EPTTTATPRGTPTPAP.
These canonical sequences were sometimes separate in some
PSA protein sequences but became closer, thanks to link cysteines
which form a disulphide bridge. Among Leishmania species, the
E34PC sequence was partially conserved in the PSA protein
sequences. The PSA sequences from L. donovani and L. infantum
were found to be the most closely related with 67.6% identity/
76.5% similarity and 53.8% identity/61.5% similarity, respectively.
DISCUSSION
Wild and domestic dogs are considered to be the main reservoir of
L. infantum/L. chagasi, responsible for ZVL.6 Several drugs are used
to cure symptomatic dogs, but infected asymptomatic ones are
not included because they are not diagnosed, thus contributing to
parasite transmission. In this context, vaccination is a key to
interrupting parasite transmission. However, research may be
hampered by requirements linked to the development of a
vaccine directed against a parasitic and neglected infectious
disease. The ideal vaccine must ensure large-scale, reproducible
Fig. 3 In vitro anti-leishmanial activity of canine monocyte-derived macrophages in non-immune and immune dogs. Canine monocyte-
derived macrophages were cultured for 5 days, then infected and exposed to autologous lymphocytes. Their anti-leishmanial activity was
expressed as the percentage inhibition of parasitic index and was evaluated before immunization (T0, placebo n= 2, vaccinated n= 5) and
two (T2, placebo n= 5, vaccinated n= 9), three (T3, placebo n= 5, vaccinated n= 8) and four (T4, placebo n= 5, vaccinated n= 9) months
after the third dose of vaccine. Dots represent individual animals and lines represent means. Asterisks (*) indicate signiﬁcant mean differences
(**p < 0.01, ***p < 0.001) measured with the Mann–Whitney–Wilcoxon test.
Fig. 4 IFN-γ and NO derivative (NO3−/NO2−) production by canine macrophages co-cultured for 72 h with autologous lymphocytes from dogs
in control and vaccinated groups. a IFN-γ levels were determined by a two-site sandwich ELISA in cell culture supernatants. b NO3−/NO2−
accumulation in the same samples was used as an indicator of NO production by activated macrophages. IFN-γ and NO derivative
productions were determined before (T0) and two months (T2) after the third dose of vaccine. Dots represent individual animals and lines
represent means. Asterisks (*) indicate signiﬁcant mean differences (**p < 0.01, ***p < 0.001) measured using a Mann–Whitney–Wilcoxon test.
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and cost-effective production, and obviously have no or only
limited side effects. A peptide-based vaccine would be an
effective way to solve these problems. Immunodominant peptides
from a Leishmania protein of interest were tested as a vaccine, to
evaluate their effectiveness against an experimental CVL, by
analyzing the induced speciﬁc immune response after vaccination
and the protection rate after infection of the dogs.
Here, we report that three immunizations with a combination of
three synthetic peptides adjuvanted with QA-21, conferred
satisfactory cross-protection against an experimental challenge
with virulent L. infantum promastigotes in dog. Live parasites from
bone marrow aspirates, a sign of active infection, were not
detected in 70% of vaccinated dogs at 6 months PC, whereas all
the dogs in the control group were found to be positive at this
Fig. 5 Conservation of peptide sequences among Leishmania species. a PSA protein sequences from different Leishmania species were aligned
with A17G, A17E and E34PC peptide sequences using the MUltiple Sequence Comparison by Log-Expectation (MUSCLE) tool. An asterisk (*)
indicates positions which have a single, fully conserved residue; a colon (:) indicates conservation between groups of strongly similar
properties; a period (.) indicates conservation between groups of weakly similar properties. The full frame, dashed frame and dotted frame
represent the E34PC, the A17E and the A17G peptide sequence localizations, respectively. b Percentages of identity, similarity and gap
between A17G, A17E and E34PC peptide sequences and PSA protein sequences from different Leishmania species were calculated on query
cover using the EMBOSS Water tool. Percentages were calculated with BLOSUM 30 matrix with the default gap open at 10 and gap extend
of 0.5.
E. Petitdidier et al.
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time point. The parasite burden of the infected vaccinated dogs
was signiﬁcantly lower than that of dogs in the control group.
Humoral and cellular immune responses revealed clear differences
between vaccinated and control dogs. The peptide-based vaccine
provided protection by inducing a Th1-type cellular immune
response: production of IFN-γ and NO derivatives led to
intracellular parasite killing. The cellular response was associated
with early production of speciﬁc anti-E34PC-peptide IgG2
antibodies, and also with the production of speciﬁc antibodies
targeting the excretory/secretory products of L. infantum (LiESAp),
which have been correlated with protection.18,19 While it has been
demonstrated that IgG1 antibodies are associated with suscept-
ibility, disease severity and correlate with a Th2 response, IgG2
antibodies are predominant in naturally resistant or vaccinated
dogs and are associated with an appropriate dominant Th1-type
immune response.23,26
In a previous study, we showed that vaccination with crude
LiESAp adjuvanted with muramyl dipeptide (MDP) conferred 100%
protection (with a dominant Th1-type response) against an
experimental infection with L. infantum promastigotes.18 More-
over, LiESAp adjuvanted with QA-21 protected dogs exposed to
two L. infantum transmission seasons in two endemic areas of the
Mediterranean basin.27 Thanks to these previous studies, which
enabled the successful development of the efﬁcient CaniLeish®
vaccine,18–20,26–28 we identiﬁed the secretome as an optimal
starting point for the next generation of vaccines against canine
leishmaniasis. Based on this observation, in another study, we
showed that a rPSA was selectively recognized by sera from
LiESAp/QA-21-vaccinated and protected dogs.22 More recently, we
proved that a vaccine composed of rPSA (LaPSA-38S, 371 amino
acids), or its carboxy-terminal part (LaPSA-12S, 119 amino acids,
representing 32% of the entire rPSA), adjuvanted with 60 µg of
QA-21, conferred respectively 78% and 80% of protection against
an experimental L. infantum infection to vaccinated dogs.23 In the
present study, we demonstrate that three short peptides (72
amino acids, representing 19.4% of rPSA), derived from this rPSA
and formulated with only 20 µg of QA-21, protected 70% (using
culture) and 60% (by detecting parasite DNA using q-PCR) of
vaccinated dogs against an experimental L. infantum infection.
These represent a signiﬁcant percentage considering (i) the
immunogenic peptides represent a small fraction of the full
recombinant protein tested previously and (ii) the decrease in the
adjuvant dose, used in this vaccine formulation which can be
optimized in future formulations. Some of the ﬁrst evidence that a
peptide-based vaccine could provide protection against Leishma-
nia infection was obtained with experimental mouse models. Two
T-cell epitope peptides derived from gp63, one of the main
surface glycoproteins of L. major, provided signiﬁcant protection
to CBA mice against severe cutaneous lesions.29 Many studies on
Leishmania antigen-derived peptide vaccines are described in
literature; for a review, see De Brito et al.30 But most studies that
describe effective protection against leishmaniasis provided by a
peptide vaccine were performed in experimental mouse models.
By comparison with similar studies done with commercially
available canine vaccines, the efﬁcacy of this peptide-based
vaccine is promising. For the Leish-Tec® vaccine (Brazilian vaccine),
Beagle dogs were immunized with 100 µg of recombinant protein
A2 adjuvanted with 250 µg of saponin, in three injections, and
then experimentally infected with 5 × 107 L. chagasi promasti-
gotes. Results showed that these immunizations were immuno-
genic and induced partial protection in dogs (43% by culturing
bone marrow aspirates).17 Regarding LetiFend® vaccine (one of
the European vaccines), Beagle dogs were vaccinated with one
injection of 100 µg of recombinant protein Q, without adjuvant,
then experimentally infected with 5 × 105 L. infantum promasti-
gotes. Parasitological evaluation was performed by culturing
lymph node and spleen samples, where 71% and 57% of the dogs
were found positive in the vaccinated group, respectively (100% in
the control group). Nevertheless, only 14% of the dogs were
parasite-DNA positive in eyelid skin samples in the vaccinated
group (85% in the control group).31
Considering initial vaccination attempts using parasite protein
components or subunits and the difﬁculties involved in producing
and purifying recombinant vaccines, the use of selected
immunodominant synthetic peptides is a promising alternative.
In recent years, peptides have emerged as the best vaccine
candidate for human use owing to their simple and cost-efﬁcient
production and development process in comparison to traditional
vaccines made of whole organisms or large proteins. Many
peptide vaccines suitable for human administration are under
development, including therapeutic anti-cancer vaccines and
vaccines against a number of human infectious diseases.32–36
Using synthetic vaccines composed of short immunodominant
peptide fragments is an attractive alternative way to elicit targeted
immune responses, consequently avoiding allergenic and/or
reactogenic sequences.32,37 However, peptides can be poorly
immunogenic and need to be delivered with additional immune-
stimulating agents, such as adjuvants or delivery systems/
carriers.38–40 The adjuvant is one of the main keys to success.
Progress in adjuvant properties and in the role of nanoparticles
inducing a Th1-type response has recently been reported.41 What
is more, chemical changes can also improve peptide vaccine
efﬁcacy, binding to MHC molecules and the overall quality of
these synthetic peptides. For example, several studies have shown
that adding a palmitoyl tail to peptides has advantages including
greatly inﬂuencing membrane permeability,42 enabling the
association with MHC class I in dendritic cells43 as well as
increasing the life span of functional presentation to cytotoxic
T cells.44
Dogs and humans share a similar type of protective immune
response against leishmaniasis, namely a polarized Th1-type
response.45–47 Results obtained in infected dogs are more reliable
and predictive than murine models and can therefore beneﬁt the
development of vaccines for humans. Moreover, the development
of vaccines able to protect canids from Leishmania infection and/
or to prevent disease progression is highly desirable not only for
the veterinary community but also for the implementation of
human leishmaniasis control programs through the reduction of
the animal reservoir.48,49 A decrease in the incidence of human
leishmaniasis after dog vaccination campaigns has been described
in Brazil,50 highlighting the importance of integrated control
programs following a ‘One Health’ approach.
Results obtained in this investigation favour the incorporation
of these peptides in a future vaccine approach for dogs and
humans. The sequence alignments showed high conservation
levels among the A17G and A17E peptide sequences and PSA
sequences from Leishmania species responsible for the most
severe leishmaniases, and partial conservation for the E34PC
sequence. Discovering the most conserved epitopes among the
antigens mediating protection from different Leishmania species
will be essential to design a polyvalent vaccine. Despite the fact
this study was performed in a short-term survey, it has to be
considered as a pilot study. However, future improvements must
be performed to relieve control programs, such as the reduction
or suppression of boosts. This would make vaccination campaigns
logistically more feasible in the areas where leishmaniasis
infections occur. Moreover, the addition of other immunodomi-
nant peptides should enhance vaccine efﬁcacy. Peptide-based
vaccines are safe, their production is simple, reproducible and
cost-effective, and they fulﬁl the necessary ﬁeld conditions such as
stability and storage temperature,51,52 which surely provide a
great opportunity to interrupt Leishmania transmission. The
encouraging results we obtained argue for the use of peptides
as promising candidates to be included in a new vaccine concept
aimed at providing large-scale protection for the target popula-
tion against leishmaniases.
E. Petitdidier et al.
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METHODS
Vaccine candidate
The peptide sequences were derived from mapped epitopes of the LaPSA-
12S protein, corresponding to the LaPSA-38S protein carboxy-terminal
region (peptide patents WO 2003025012 and WO 2009153458; LaPSA-38S
GenBank accession number: FJ974054 and UniprotKB: D1GJ50; LaPSA-12S
GenBank accession number: FJ974053.1 and UniprotKB: D1GJ49).
For the peptide design, proteasome cleavage analysis of the LaPSA-12S
protein was performed using the NetChop 2.0 Server.53,54 The putative
cleavage sites predict two 16-mer peptide sequences, named A16G and
A16E. The putative antigenicity of these two peptides was then analyzed
with VaxiJen v2.0, a prediction server for protective antigens and subunit
vaccines,55 and both peptides are predicted to be antigenic (score > 0.5).
These two peptides were modiﬁed as lipopeptides obtained with N-
terminal addition of a lysine modiﬁed by Nε-palmitoylation (K(Pal))—
peptides A17G and A17E. In the A17E peptide sequence, the cysteines of
the original peptide sequence (AARCARCREGYSLTDE) were replaced by
serines (underlined in the sequences) in order to avoid disulphide bridge
formation, folding or multimerization of the peptide. Also, an overlapping
peptide library was used to discover B-cell epitopes recognized by a
monoclonal antibody (mAb F5) directed against excreted/secreted
antigens from L. amazonensis.22 From this analysis performed by Pepscan
System company (Lelystad, The Netherlands), a 34-mer peptide has been
identiﬁed—E34P peptide. The E34P peptide was synthesized as cyclic
peptide (and named E34PC peptide) by linking the Cys9 residue to the
Cys15 residue of the peptide (underlined in the sequence) with a
chemically stable disulphide bond.56
Finally, the peptide-based vaccine comprises these three synthetic
peptides:
A17G: [K(Pal)-AASSTPSPGSGCEVDG]
A17E: [K(Pal)-AARSARSREGYSLTDE]
E34PC: [EDEHKGKYCRLGNDCRTTEPTTTATPRGTPTPAP].
Each peptide was manufactured under current good manufacturing
practice (GMP) conditions by PolyPeptide Group (PolyPeptide Laboratories,
Strasbourg, France) as a freeze-dried product. The formulated vaccine
consists in 25 µg A17G, 25 µg A17E, 10 µg E34Pc and 20 µg of QA-21 as
adjuvant. It is reconstituted in a ﬁnal volume of 1mL buffered saline
before use.
Ethics statement
This investigation conformed to the Guide for the Care and Use of
Laboratory Animals (NIH Publication No. 85–23, revised 1996). The local
Ethical Committee of the National Veterinary School of Lyon (ENVL, France)
conﬁrmed that experiments, maintenance and care of dogs complied with
guidelines of the European Convention for the Protection of Vertebrate
Animals used for Experimental and other Scientiﬁc Purposes (CETS no.
123). According to recommendations of this ethic committee for this
project (number 136/08), the number of animals and long-term
experimentations was kept to the minimum.
Animals and study design
In order to respect the “three R” rule concerning animal welfare (Replace,
Reduce, Reﬁne), sample size calculation was performed with G*Power
software, version 3.1.9.2 (University of Kiel, Germany). To compute required
sample size, we hypothesized that (i) all dogs from the control group
(unvaccinated dogs) should be infected after parasitic challenge (100% of
dogs, based on our previous studies), (ii) the vaccine should protect at least
55% of dogs to be consider as effective and (iii) a 2:1 ratio between vaccine
and placebo group should be relevant to evaluate protection level. A one-
sided test was applied, at an alpha risk of 5% and a power of 80%. Hence,
15 naive Beagle dogs were enroled in this study. Eight males and seven
females, between 2 and 4 years old, were selected on clinical and
serological criteria in the kennel CEDS (Domaine des Souches, Mezilles,
France), a non-endemic Leishmania area. The selected dogs were housed
at the animal facility of the National Veterinary School of Lyon (ENVL,
France) in the preclinical investigation unit throughout the duration of the
study under conditions to exclude any possibility of natural Leishmania
infection. Dogs were housed under the supervision of a veterinarian and
had received their routine vaccinations. They were kept in quarantine for a
period of 30 days before the study began. A speciﬁc code/ID for each dog
was used throughout the experiment. Prior to vaccination, blood was
collected from all the dogs. Genomic DNA was extracted in order to
exclude any infected dog.
Animals were randomized by gender, age and weight into two
experimental groups and the study was performed in a double-blind
randomized fashion. Dogs of each group received three subcutaneous
injections at 28 day intervals of either 1 mL buffered saline (Control group,
n= 5) or 1 mL formulated vaccine (Vaccinated group, n= 10). Four months
after the full course of vaccination, all dogs were experimentally infected
by intravenous injection of 108 infective promastigotes of L. infantum
(MHOM/MA/67/ITMAP-263 strain, clone 2). Primary cultures of virulent
promastigotes were established from amastigotes isolated from heavily
infected mice spleen (BALB/c) and used for the virulent challenge.
Clinical follow-up and assessment of parasite load
The dogs were monitored after each injection of the vaccine candidate.
Local tolerance was investigated by visual examination and any lesions
were scored daily over a period of 14 days after each injection. A daily
health check, including rectal temperature measurement, was performed.
Each dog was also weighed once a week throughout the experiment. The
health status of the animals (appetite, physical examination and physical
activity) was monitored by veterinarians. After experimental infection, dogs
were monitored for parasite establishment and subsequent development
of the disease by screening for classical clinical signs, until 6 months after
administration of the parasites. Infection of dogs was assessed by
collecting bone marrow aspirates (by sternal puncture after anaesthesia)
at 2, 4 and 6 months PC. These bone marrow samples were (i) cultured in
NNN diphasic medium at 27 °C and checked microscopically for parasite
growth weekly and (ii) used to quantify L. infantum kinetoplast DNA by
real-time q-PCR.
In detail, 0.5 mL of bone marrow samples were cultured in NNN biphasic
medium, containing 2mL of RPMI-20% heat-inactivated foetal calf serum,
for 1 week. Subcultures were performed weekly (3 in total) by adding
0.5–1mL of culture sample in NNN medium containing 3mL of RPMI-20%
FCS. Parasite presence was determined by microscopic observation in an
inverted microscope at 400x magniﬁcation. A sample was considered as
positive when live parasites were observed. For Leishmania kinetoplast
DNA ampliﬁcation, DNA of each bone marrow sample was extracted using
the QIAamp DNA mini kit (Qiagen) according to the manufacturer’s
instructions. The qPCR master mix was composed of forward primer
(CTTTTCTGGTCCTCCGGGTAGG, 15 pmol), reverse primer (CCACCCGGCCCT
ATTTTACACCAA, 15 pmol) and TaqMan probe (FAM-TTTTCGCAGAACGCC
CCTACCCGC-TAMRA, 50 pmol). Assays were performed with 1 µL of DNA
sample in a ﬁnal volume of 25 µL. Standard curve was established from
Leishmania gDNA extracted from 5 × 106 parasites: 1 µL of each serial
dilution, ranging from 5 × 104 to 10−4 parasites, was introduced into
reaction tubes. Comparative quantiﬁcation was performed using the
polymerase gene as house-keeping gene. This gene was ampliﬁed with a
forward primer (TGTCGCTTGCAGACCAGATG, 200 pmol), reverse primer
(GCATCGCAGGTGTGAGCAC, 200 pmol) and TaqMan probe (VIC-CCAGG
CTCGAAGTTGTTGCTGCCC-TAMRA, 200 pmol). Reactions were performed
on the Stratagene MX4000 Real-Time QPCR System (La Jolla, California,
USA) using two-step temperatures (94 °C and 55 °C) cycling over 45 cycles.
A sample was considered as positive when the established parasite
concentration was superior to 40 parasites per millilitre.
Detection of speciﬁc IgG2 to LiESAp and E34PC peptide by ELISA
Speciﬁc IgG2 antibody responses against L. infantum promastigote
excreted/secreted antigens (LiESAp) and E34PC peptide were measured
in the serum samples of all the dogs in both the control and vaccinated
groups. These assays were performed prior to immunization and 2 and
3 months after immunization using a standard ELISA procedure.19,23 Brieﬂy,
sera were added in triplicate at 1/100 dilution in PBS containing 0.05%
Tween-20 (PBS-T) to 96-well plates (Nunc MaxiSorp™ Flat bottom 96-well
plates) previously coated with LiESAp (0.1 µg per well) or E34PC peptide
(0.1 µg per well), and incubated for 1 h at 37 °C. After incubation and three
washes in PBS-T, the plates were incubated for 30min at 37 °C with
secondary antibody (horseradish peroxidase-conjugated sheep anti-dog
IgG2, 1/5000) (Bethyl Laboratories, Inc., Mongomery, TX, catalogue number
A40-121P). After washing in PBS-T, plates were then developed with o-
phenylenediamine dihydrochloride (OPD) substrate in the dark and
absorbance was read at 492 nm. For analysis, a positivity threshold was
calculated using the following formula: mean OD in sera collected from all
dogs at the starting point (before immunization)+ 3 standard deviations.
Humoral response was considered positive when the IgG2 titre was above
the positivity threshold.
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Assessment of canine monocyte-derived macrophage anti-
leishmanial activity
An ex vivo canine macrophage-autologous lymphocyte co-culture system
was used to investigate the ability of macrophages to kill intracellular
Leishmania parasites. Brieﬂy, peripheral blood mononuclear cells (PBMCs)
were obtained from heparinized peripheral blood by density centrifuga-
tion through Ficoll-Hypaque (GE Healthcare Life Sciences). Canine
monocyte-derived macrophages (CM-DM) were isolated from lymphocytes
by differential adherence. CM-DM were cultured for 5 days at 37 °C and 5%
CO2 in RPMI 1640 medium (BioWhittaker, Inc., Walkersville, MD),
supplemented with 2mM glutamine, 10% heat-inactivated FCS, 100 µg/
mL streptomycin and 100 IU/mL penicillin. They were then infected with
stationary-phase promastigotes of L. infantum (MHOM/MA/67/ITMAP-
263 strain, clone 2) at a parasite:macrophage ratio of 5:1 for 150min in
16-well glass culture slides (Nunc™ Lab-Tek™ II Chamber Slide™). After serial
washings to remove non-internalized parasites, infected macrophages
were incubated alone or in the presence of autologous lymphocytes
(previously maintained in culture at 37 °C and 5% CO2 in RPMI 1640
medium supplemented with 2mM glutamine, 10% heat-inactivated FCS,
100 µg/mL streptomycin and 100 IU/mL penicillin) at a lymphocyte:
macrophage ratio of 2:1 and incubated for 72 h at 37 °C and 5% CO2.
Supernatants were then collected for further analyses and macrophages
were ﬁxed with methanol and stained with Giemsa. To assess the anti-
leishmanial activity, the percentages of infected cells and the number of
amastigotes per macrophage were estimated in duplicate experiments by
microscopic examination and used to calculate the parasite index (PI)
inhibition. Percentage of PI inhibition= 100− [(mean number of amasti-
gotes per macrophage × percentage of infected macrophages when
macrophages were co-cultured with autologous lymphocytes)/(mean
number of amastigotes per macrophage × percentage of infected macro-
phages in non-co-cultured macrophages)] × 100.
IFN-γ cytokine and NO measurements
Supernatants were collected from macrophages infected 72 h previously
and co-cultured with autologous lymphocytes. IFN-γ levels in cell culture
supernatants were assessed in triplicate experiments by a quantitative
sandwich ELISA according to the manufacturer’s instructions (Canine IFN-γ
DuoSet ELISA, R&D Systems, Minneapolis, USA, catalogue number DY781).
Nitrate (NO3
−)/nitrite (NO2
−) accumulation in supernatants was measured
in triplicate experiments by the Griess reaction as an indicator of NO
production by activated macrophages. This colorimetric assay was used
following the manufacturer’s instructions (Nitric Oxide (NO3
−/NO2
−)
detection kit, Alexis biochemicals, Enzo Life Sciences, France).
Bioinformatic studies
The A17G, A17E and E34PC peptide sequences were derived from the
LaPSA-38S protein sequence (GenBank accession number: FJ974054;22
UniprotKB D1GJ50). PSA protein sequences from the other Leishmania
species were obtained from Basic Local Alignment Search Tool (BLAST)
algorithm (https://blast.ncbi.nlm.nih.gov/). The sequences closest to LaPSA-
38S protein sequence were selected to align with peptide sequences.
Putative or hypothetical protein sequences were rejected. The Multiple
Sequence Comparison by Log Expectation (MUSCLE) tool (https://www.ebi.
ac.uk/Tools/msa/muscle/) was used to align all the selected PSA protein
sequences. The pairwise sequence local alignments were obtained using
the EMBOSS Water tool (https://www.ebi.ac.uk/Tools/psa/emboss_water/).
Percentage identity and similarity were calculated with matrix BLOSUM30
and the default gap open of 10 and gap extend of 0.5.
Statistical analysis
Data analysis was performed with GraphPad Prism version 5.03 for
Windows (GraphPad Software, San Diego, USA). The statistical signiﬁcance
of differences between independent sample groups was determined with
the Mann–Whitney–Wilcoxon test and Fisher’s exact test for contingency
table analyses. One-sided tests were applied at an alpha risk of 5%. A p-
value ≤ 0.05 was considered signiﬁcant.
Reporting Summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
DATA AVAILABILITY
The data supporting the ﬁndings of the study are available from the corresponding
authors upon reasonable request.
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